Lung Cancer
From the Journals
Rechallenge ‘reasonable’ for some with small-cell lung cancer
Carboplatin plus etoposide significantly prolonged progression-free survival, compared with topotecan, in patients with advanced or relapsed,...
From the Journals
Lung cancer CT scan is chance for ‘opportunistic’ osteoporosis check
"CT provides a more direct volumetric measure [than DXA] and is likely a more accurate method for BMD assessment," one expert says.
From the Journals
Black patients with ES-SCLC get less chemo but have better survival
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
News from the FDA/CDC
50.6 million tobacco users are not a homogeneous group
Traditional cigarettes are the still the most popular choice, but young adults prefer the electronic variety.
Conference Coverage
Risk factors for severe immune-related AEs identified
A nationwide cohort study of more than 14,000 patients finds combination immune checkpoint inhibitor therapy, younger age, and a lung cancer...
Conference Coverage
Lung cancer: Proton beam radiotherapy likely reduces cardiovascular events
A retrospective study shows lower rates of transient ischemic attack and MI with proton beam radiotherapy.
From the Journals
Adding cetuximab to afatinib provides no benefit in EGFR-mutant NSCLC
Survival outcomes were similar whether patients received afatinib alone or afatinib plus cetuximab.
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
National lung cancer screening guidelines may miss younger African American individuals at high risk
Retrospective analysis finds many lung cancer patients would not have counted as eligible for low-dose CT under guidelines that are being...